Universität zu Köln

Heldwein, Matthias B., Schlachtenberger, Georg ORCID: 0000-0001-7118-8432, Doerr, Fabian, Menghesha, Hruy, Bennink, Gerardus, Schroeder, Karl-Moritz, Schaefer, Stephan C., Wahlers, Thorsten and Hekmat, Khosro (2022). Different pulmonary adenocarcinoma growth patterns significantly affect survival. Surg. Oncol.-Oxf., 40. OXFORD: ELSEVIER SCI LTD. ISSN 1879-3320

Full text not available from this repository.

Abstract

Objective: Adenocarcinoma (AC) is the number one pathological entity of lung cancer with approximately 30-40% of cases. It is known to be heterogeneous and has 5 histopathological growth patterns. We evaluated the long-term survival rates of patients with predominant subtypes. Methods: 290 patients with AC underwent pulmonary resection between 2012 and 2017 at our institution. We excluded all patients with lymph node involvement and distant metastases. Hence, 163 patients were included for further analysis. Predominant growth pattern was defined if more than 10% of cells showed a growth pattern. 1, 3, and 5-year survival rates were evaluated. Survival was assessed by Kaplan-Meier curves and the Cox proportional hazards model was used to identify prognostic factors for overall survival. Results: Predominant growth patterns > 10% were compared to < 10% growth patterns of the same subtype. 1 year, 3-year, and 5-year overall survival rates of patients with predominant solid tumor growth > 10% differed significantly from patients with < 10% (88.4% vs. 97.6%, p = 0.04; 65.8% vs. 87.4% p = 0.001, 36.4% vs. 65.9% p = 0.01). Survival rates did not differ between > 10% papillary and acinar growth compared to < 10%. Kaplan-Meier curves showed reduced overall survival for patients with solid tumor growth > 10% (log-rank 0.002). Solid tumor growth > 10% was an independent prognostic factor for worse long-term survival (Hazard ratio: 3.05, p = 0.01). Conclusion: Our study demonstrates that the presence of a predominant solid pattern in pulmonary adenocarcinoma is a factor for an unfavorable prognosis. This should be kept in mind in daily clinical practice.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Heldwein, Matthias B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlachtenberger, Georg UNSPECIFIED orcid.org/0000-0001-7118-8432 UNSPECIFIED Doerr, Fabian UNSPECIFIED UNSPECIFIED UNSPECIFIED Menghesha, Hruy UNSPECIFIED UNSPECIFIED UNSPECIFIED Bennink, Gerardus UNSPECIFIED UNSPECIFIED UNSPECIFIED Schroeder, Karl-Moritz UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaefer, Stephan C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wahlers, Thorsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Hekmat, Khosro UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-663980
DOI:	10.1016/j.suronc.2021.101674
Journal or Publication Title:	Surg. Oncol.-Oxf.
Volume:	40
Date:	2022
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1879-3320
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL LUNG-CANCER; ADJUVANT CHEMOTHERAPY; INTERNATIONAL-ASSOCIATION; IASLC/ATS/ERS CLASSIFICATION; CISPLATIN; BENEFITS; SUBTYPE; DISEASE; TRENDS; IMPACT Multiple languages Oncology; Surgery Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66398